68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

This is an expanded access study with a total of 300 participants with NET and suspected
SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment.
Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All
patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and
then accepted for scanning if clinically appropriate.

Inclusion Criteria:

- Older than 18 years the time of radiotracer administration

- Provides written informed consent

- Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age
must have a negative pregnancy test at screening/baseline

- Able to remain still for duration of each imaging procedure (about 30 minutes)

Exclusion Criteria:

- Less than 18 years-old at the time of radiotracer administration

- Pregnant or nursing

- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

- Any additional medical condition, serious concurrent illness, or other extenuating
circumstance that, in the opinion of the Investigator, may significantly interfere
with study compliance.